Finding. Crohn's stool already carries extra mesaconate, just not enough, and the colon drinks it before it can work. Qian, Acharya and colleagues build two ways to keep it there: a zinc-crosslinked mesaconate material, and Escherichia coli Nissle 1917 engineered to overexpress cis-aconitate decarboxylase so itaconate can become mesaconate. The metabolite rewires T cells: glycolytic activity down, mitochondrial activity down, RORγt down. In SAMP1/YitFC steroid-withdrawal mice and in TNFDARE mice, the zinc material lowers gut permeability and drops myeloperoxidase a thousand-fold versus controls. The probiotic lowers RORγt in CD4 and CD8 T cells, permeability, and inflammation in preventive and withdrawal SAMP1/YitFC experiments.
Why this paper matters
Itaconate has a mitochondrial fan club. Mesaconate is the sibling that actually shows up in Crohn's stool. The translational problem was pharmacokinetics, not discovery. Two gut-restricted delivery systems plus a T-cell bioenergetic downshift is a complete-enough preclinical package to file. The mitochondrial claim is part of a broader T-cell quieting, not a Complex I story.
What they actually measured
Material and probiotic pharmacokinetics-by-phenotype, T-cell RORγt and bioenergetic language, two Crohn's-like mouse systems, permeability and MPO. CAD is the itaconate-producing enzyme; MES is the effector they care about.
How to read the score
High 70s. Real T-cell mitochondrial downshift, strong in vivo numbers, delivery invention. Confidence is medium until the 1,000-fold MPO and the mitochondrial assay are seen.
Caveats
Mouse only. Mitochondrial activity is unspecified. Engineered EcN in inflamed gut has its own risk conversation. Do not ship mesaconate to patients from this brief.
What to do with it
If you work on itaconate-family immunometabolism, add mesaconate and a T-cell OCR/ECAR panel. If you build gut-restricted metabolites, steal the Zn-crosslink and CAD-probiotic pairing. Check the MPO figure before you quote 1,000-fold.